Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
1.42
-0.01 (-1.04%)
Market open: Aug 12, 2026, 11:45 AM EDT
1.44
0.00 (0.00%)
Previous after-hours: Aug 11, 2026, 7:11 PM EDT
Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia for the treatment of female sexual arousal disorder; DARE-HRT1 to treat vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of dyspareunia or pain during sexual intercourse; and DARE-HPV, a fixed-dose formulation of lopinavir and ritonavir in a soft gel vaginal insert to treat genital human papillomavirus (HPV) infection, cervical intraepithelial neoplasia, and other HPV-related pathologies. In addition, the company develops DARE-PDM1, a hydrogel formulation of diclofenac for vaginal administration to treat primary dysmenorrhea; DARE-204 and DARE-214, injectable formulations of etonogestrel that provides contraception over 6-month and 12-month periods; DARE-FRT1 and DARE-PTB1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB2 for the prevention of preterm birth. Further, it develops DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design controlled contraceptive option; DARE-RH1, an approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein; and DARE-GML, which delivers antimicrobial glycerol monolaurate intravaginally. It has a strategic collaboration with MyMenopauseRx. Daré Bioscience, Inc. was founded in 2015 and is headquartered in San Diego, California.
There is no data to display
| Date | Type | Document |
|---|---|---|
| 2026-07-24 | 8-K | form8-k.htm |
| 2026-07-17 | 253G2 | a253g2regaofferingcircular.htm |
| 2026-07-13 | 8-K | form8-k.htm |
| 2026-06-23 | S-8 | forms-8.htm |
| 2026-06-22 | 8-K | form8-k.htm |
| 2026-06-12 | 8-K | dare-20260611.htm |
| 2026-06-01 | DEFA14A | formdefa14a.htm |
| 2026-05-18 | 8-K | dare-20260514.htm |
| 2026-05-15 | 253G2 | a253g2regaofferingcircular.htm |
| 2026-05-14 | 8-K | dare-20260514.htm |